Drug costs 'will push millions into poverty'
London, September 1, 2010
Tens of millions of people in low and middle income countries would be pushed below the poverty line by buying common but vital medicines which are already unaffordable to hundreds of millions more, a study has found.
Laurens Niens' team at Erasmus University Rotterdam analysed the number of people who would be pushed below an income level of $1.25 or $2 a day -- poverty indicators used by the World Bank -- by paying for four important, widely used medicines.
The Dutch researchers whose work was published in the Public Library of Science (PLoS) Medicine journal on Tuesday said their findings showed that greater effort is needed to encourage the use of cheaper generic drugs in poor countries and to ensure more medicines are made available through the public sector.
The drugs studied were a salbutamol inhaler, used for the management of asthma, glibenclamide, a common diabetes drug, atenolol, which belongs to a drug class commonly known as beta-blockers and is used to treat high blood pressure, and amoxicillin, a broad spectrum antibiotic.
Using data from the World Bank and the World Health Organisation, the researchers generated "impoverishment rates" for these medicines in 16 low- and middle-income countries.
The results of their study show the much greater impoverishing effect of branded drugs which are sometimes the only option available in countries where public sector provision is often patchy.
In Yemen, for example, where seven percent of people live on less than $1.25 a day, buying branded glibenclamide -- sold as Daonil by Sanofi-Aventis -- would impoverish another 22 percent, but buying the cheapest generic equivalent would only push another 3 percent below the poverty line.
In Nigeria, amoxicillin is already unaffordable to the 56 percent of the population who live on less than $1.25 per day. A further 23 percent of Nigerians would be pushed into poverty by by having to buy branded version Amoxil, made by GlaxoSmithKline, while only another 12 percent would be impoverished by buying the cheapest generic version, the study said. - Reuters
More Health & Environment Stories
- Dubai Healthcare City inks deal with UAE universities
- University of Ain Shams opens MS treatment unit
- Bahrain's humidity could ease water crisis
- Visibility in Bahrain forecast to improve
- Bahrain-India venture plans hospitals in GCC
- Seha launches new health initiative
- Veolia backs Oman waste management meet
- Obesity rate at 72pc among Saudi adults
- Bahrain ideal for artificial rain experiment
- Riyadh 'among most polluted cities'
- CGM acquires 3 European healthcare IT providers
- The age of genomic medicine dawns, finally
- Over 300 exhibitors for Saudi healthcare event
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman